Literature DB >> 24690150

Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice.

Zhong-Yuan Li1, Jia Chen2, Eskild Petersen3, Dong-Hui Zhou4, Si-Yang Huang4, Hui-Qun Song4, Xing-Quan Zhu5.   

Abstract

The synergistic protective efficacy of murine interleukin 21 (mIL-21) and mIL-15 administrated with DNA vaccine against acute and chronic Toxoplasma gondii infection in mice was investigated using T. gondii MIC8 (TgMIC8) as a model. We cloned mIL-21 and mIL-15 from splenic tissues of Kunming mice, and constructed eukaryotic plasmid pVAX/mIL-15, pVAX/mIL-21, and pVAX/mIL-21/mIL-15, respectively. After immunizing with pVAX/TgMIC8 in the presence or absence of these cytokines, immune responses were analyzed using lymphoproliferative assay, cytokine and serum antibody measurements, flow cytometric surface markers on lymphocytes and protection against acute and chronic T. gondii infection. Mice receiving pVAX/TgMIC8 alone developed a strong humoral responses and Th1 type cellular immune responses, and showed an increase of CD4+ and CD8+ T cells compared with all the controls. Adding pVAX/mIL-21 to pVAX/TgMIC8 compared to pVAX/TgMIC8 resulted in only a slight increase in humoral and cellular immune responses, and this immune response was lower than that induced by the pVAX/mIL-15 combined with pVAX/TgMIC8. Co-administration of pVAX/mIL-21/mIL-15 combined with pVAX/TgMIC8 elicited the strongest humoral and cellular immune responses among all the groups, leading to significantly increased survival time against acute infection and the significant reduction of tissue cysts, compared to all the controls. Synergy of mIL-21 and mIL-15 can facilitate specific humoral as well as cellular immune responses elicited by DNA vaccine against acute and chronic T. gondii infection in mice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA vaccine; Protective immunity; Synergy; TgMIC8; Toxoplasma gondii; Toxoplasmosis; mIL-15; mIL-21

Mesh:

Substances:

Year:  2014        PMID: 24690150     DOI: 10.1016/j.vaccine.2014.03.042

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Authors:  Rosalie C Warner; Ryan C Chapman; Brianna N Davis; Paul H Davis
Journal:  J Parasitol       Date:  2021-11-01       Impact factor: 1.276

2.  Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.

Authors:  Nahiara Esteves Zorgi; Andrés Jimenez Galisteo; Maria Notomi Sato; Nanci do Nascimento; Heitor Franco de Andrade
Journal:  Med Microbiol Immunol       Date:  2016-01-05       Impact factor: 3.402

Review 3.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217

4.  A Novel Combined DNA Vaccine Encoding Toxoplasma gondii SAG1 and ROP18 Provokes Protective Immunity Against a Lethal Challenge in Mice.

Authors:  Lamei Wu; Huijian Yang; Jianglin Wang; Xiuwen Yu; Yanhong He; Shenxia Chen
Journal:  Acta Parasitol       Date:  2021-05-21       Impact factor: 1.440

Review 5.  Recent advances in Toxoplasma gondii immunotherapeutics.

Authors:  Sherene Swee-Yin Lim; Rofina Yasmin Othman
Journal:  Korean J Parasitol       Date:  2014-12-23       Impact factor: 1.341

Review 6.  Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.

Authors:  John J Suschak; James A Williams; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

7.  Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection.

Authors:  Su-Hwa Lee; Ah-Ra Kim; Dong-Hun Lee; Ilaria Rubino; Hyo-Jick Choi; Fu-Shi Quan
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

8.  Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice.

Authors:  Jia Chen; Zhong-Yuan Li; Si-Yang Huang; Eskild Petersen; Hui-Qun Song; Dong-Hui Zhou; Xing-Quan Zhu
Journal:  BMC Infect Dis       Date:  2014-09-06       Impact factor: 3.090

9.  DNA vaccination with a gene encoding Toxoplasma gondii Rhoptry Protein 17 induces partial protective immunity against lethal challenge in mice.

Authors:  Hai-Long Wang; Yu-Jing Wang; Yan-Jiang Pei; Ji-Zhong Bai; Li-Tian Yin; Rui Guo; Guo-Rong Yin
Journal:  Parasite       Date:  2016-02-03       Impact factor: 3.000

Review 10.  Calcium-dependent protein kinases are potential targets for Toxoplasma gondii vaccine.

Authors:  Masoud Foroutan; Fatemeh Ghaffarifar
Journal:  Clin Exp Vaccine Res       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.